Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Open Access

Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Gerardo Rodríguez‐LobatoOCOriol CardúsJMJoan Mañé-Pujol

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved control of myeloma in cells with limited BCMA, suggesting CD229's role.

Key Points

  • Control of myeloma was effective with bicistronic CAR T cells targeting BCMA and CD229, even with low BCMA expression.
  • The study involved K562 tumor cell line clones, showing variability in CD229 expression gradient during experiments.
  • Clonal assessment revealed the potential of dual targeting to enhance myeloma treatment outcomes despite BCMA limitations.
  • Results imply a synergistic effect between BCMA and CD229 targeting in CAR T cell therapies for myeloma.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb5ahttps://doi.org/10.1158/2326-6066.30029635
View Full Paper
Ask AI
Bookmark
Share